We also examined the combination of Bcl9 depletion and anti-PD-1 in MC38 tumors compared to NT-shRNA tumors and confirmed that depletion of Bcl9 decreases tumor size in response to anti-PD-1, with a TGI of 87.1% by day 18 (Fig. 2f). Here, BCL9 is linked to neoplasm.